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Abstract 
Nanotechnology provide innovative tools that shed greater light on life cycle of normal  cells and 
the point at which molecular processes and changes within cells become correlated with development of 
cancer. It should be possible to obtain large amount of information from a small source. They aid in 
analysis of parameters such as cellular mechanics, morphology and cytoskeleton which has been hard to 
achieve using conventional technology. 
Nano devices can detect cancer cells, identify cancer signatures and provide targeted delivery of 
anti cancer therapeutics and contrast agents to tumour cells.  The obstacle to early detection of cancer lies 
in the liability of existing tools to detect molecular level changes during early phases in the development 
of cancer. Nano Technology is potential tool that could help detect the molecular changes and assist in 
focusing on preventive efforts.  
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Introduction 
  Nanotechnology is an area of science 
devoted to the manipulation of atoms and 
molecules leading to the construction of 
structures in the nanometer scale size range 
(often 100nm or smaller) which retain unique 
properties. NT deals with structures that range 
from 1 to l00nm- about the size of a virus – and 
derives its name from Greek word for “dwarf”5. 
“NT allows us to make materials that are 
thousands of times smaller than the smallest cell 
in the body “said James R Baker Jr, MD, 
Professor of biologic NT at University of 
Michigan in Ann Arbor. Because these materials 
are so small, they can easily get inside cells and 
change how they work5. 
  NT is considered as an emerging 
technology that can have enormous positive 
impact on human health. Relevant Process of 
living organisms occur basically at nanometer 
scale, elementary biological units like DNA, 
Proteins  or cell membranes are of this 
dimenision4. Nanoscale devices smaller than 
50nm can easily enter most cells and those 
smaller than 20nm can move out of blood 
vessels as they Circulate through the body. Early 
detection of disease is often critical to how 
successful treatment can be. Therefore the 
development of new methods of diagnosis is a 
hot research field, where every small step is of 
great importance. The potential applications are 
predominantly in detection, diagnostics (disease 
diagnosis and imaging), monitoring and 
therapeutics. 
Discussion 
  Products based on NT in medicine and 
medical technology are reaching the market with 
an anticipated enormous Positive impact on 
human health, in coming years. 
  NT can have an impact on the key 
challenges in cancer diagnosis and therapy. 
Nanotechnology’s greatest advantage over 
conventional therapies may be the ability to 
combine more than one function. There is a lot 
of research going on to design novel nano 
devices capable of detecting cancer at its earliest 
stages, pinpointing its location with in the 
human body and delivering chemotherapeutic 
drugs against malignant cells.  
  The major area in which nanomedicine 
is being developed in cancer involves. 102 
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a)  Early detection of tumours (analysis of 
cancer associated markers and designing 
contrast agents that improve the 
resolution of tumour area comparing 
with the nearby normal tissues) 
b)  Cancer treatment (Creating nanodevices 
that can release chemotherapeutic 
agents)   
Tumour diagnostics and prevention  
Prevention is the best cure for Cancer. 
Early detection will greatly increase survival 
rates an in situ tumour will be easier to 
eradicate than one that has metastasized4. 
  Different kinds of nanoparticles suitable 
for drug and gene delivery, probing DNA 
structures etc. include  
1.  Liposomes 
2.  Polymeric Nanoparticles (Nano spheres 
and Nano capsules) 
3.  Solid lipid particles 
4.  Nano crystals 
5.  Polymer Therapeutics such as dendrimers, 
fullerenes. 
6.  Inorganic Nanoparticles (eg. Gold & 
Magnetic Nano particles) 
  Dendritic polymeric nano devices can 
detect cancer cells, identify cancer signatures and 
provide targeted delivery of anti cancer 
therapeutics. (i.e. Cis-platin, Methotrexate and 
Taxol) and contrast agents to tumour cells.   The 
polymers show uniform uptake in cells and 
survive for more than two weeks inside the cells 
and do seem to be affected by body’s multidrug 
resistance processes.  The size of polymers is 
under filtration threshold of kidney and cannot 
cross blood brain barrier.  Since there is nothing 
for host’s cells to bind to, there is no immune 
reactivity.   
   Carbon nanotubes scan down DNA 
and look for single nucleotide polymorphism 
which make possible to detect whether an 
individual has a high-risk or low-risk 
configuration for developing the processes that 
lead to cancer.  This technique can serve as an 
alternative to PCR and identify multiple 
nucleotide polymorphic sites in large strands on 
non amplified DNA at relatively high through 
put and low cost. 
  Nanowires having the unique properties 
of selectivity and specifity can be designed to 
sense molecular markers of malignant cells. 
They are laid down across a micro fluidic 
channel and they allow cells or particles to flow 
through it. Nanowires can be coated with a 
probe such as an antibody or oligonucleotide, a 
short stretch of DNA that can be used to 
recognize. Proteins that bind to the antibody 
will change the nanowires electrical 
conductance and this can be measured by a 
detector. As a result, proteins produced by 
cancer cells can be detected and earlier 
diagnosis of tumour can be achieved. 
Nanoparticle Contrast agents are being 
developed for tumour detection purposes. 
Labelled and nonlabelled nanoparticles are 
already being tested as imaging agents in 
diagnostic procedures such as nuclear magnetic 
resonance imaging. Such nanoparticles are 
paramagnetic ones, consisting of an inorganic 
core of iron oxide coated or not with polymers 
like dextran. There are two main groups of 
nanoparticles 
1)  Super paramagnetic iron oxides whose 
diameter size is greater than 50nm 
2)  Ultra small super magnetic iron oxides 
whose nanoparticles are smaller than 50nm 
   Quantum dots being the nanoscale 
crystals of a semiconductor material such as 
cadmium selenide, can be used to measure 
levels of cancer markers such as breast cancer 
marker Her-2, actin, micro fibril proteins and 
nuclear antigens.4 
         Gold nanoparticles used as optical probes 
for early detection of oral cancer. They can be 
conjugated to antibodies or peptides through 
electrostatic interaction or coordinate bonding 
to probe for specific cellular biomarkers 
(EGFR) with high specificity and affinity. Gold 
nanoparticles provide useful optical signals for 
molecular specific information. 
         Nano-Bio-Chip sensor technique found 
to be promising new diagnostic tool for early 
detection of oral cancer. Further trials need to 
establish their effectiveness. 
Tumour treatment 
  Frequent challenges encountered by 
current cancer therapies include nonspecific 
distribution of antitumour agent, inadequate 
drug concentrations reaching the tumour, and 103 
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limited ability to monitor therapeutic responses. 
Poor drug delivering to the target site leads to 
significant complication, such as multidrug 
resistance.1 Current NT promises solutions to 
several of the current obstacles facing cancer 
therapies. Nanoparticles have size of 5nm to 
200nm, allowing their unique interaction with 
biological systems at the molecular level. As a 
result of their materials composition, 
nanoparticles are capable of self assembly and 
maintaining stability and specificity which are 
crucial to drug encapsulation and 
biocompatibility. 
  Nanoparticlaes used as drug delivery 
vehicles are generally <100nm in at least one 
dimension and consist of different 
biodegradable materials such as natural or 
synthetic polymers, lipids or metals. For 
therapeutic applications drugs can either be 
integrated in the matrix of the particle or 
attached to the particle surface2 
  An effective approach for achieving 
efficient drug delivery would be to rationally 
develop nanosystems based on the 
understanding of their interaction with the 
biological environment, target cell population, 
target cell surface receptors, changes in cell 
receptors that occur with progression of disease, 
mechanism and site of drug action, drug 
retention, multiple drug administration, 
molecular mechanism and patho biology of the 
disease under consideration2. 
  Nanoparticles can consist of a number 
of materials, including polymers, metals and 
ceramics. Many types of nanoparticles are under 
various stages of development as drug delivery 
systems, including liposomes and lipid based 
carriers (such as lipid emulsions and lipid –drug 
conjugates, polymer microspheres, micelles and 
various ligand – targeted products (such as 
immunoconjugates).5 
        Liposomes and other lipid based 
nanoparticles liposomes are self assembling, 
spherical, closed colloidal structures composed 
of lipid bilayers that surround a central aqueous 
space. Liposomes are most studied formulation 
of nanoparticle for drug delivery. Liposomal 
formulation has shown an ability to improve the 
pharmakinetics and pharmodynamics of 
associated drugs. One strategy to achieve 
tumour-specific targeting is to conjugate a 
targeting moiety on the outer surface of the lipid 
bilayer of the liposome that selectively delivers 
drug to the desired site of action1. 
Polymeric Nano Particles       
  Nano particles can be coated with 
hydrophilic polymers. Coating can efficiently 
protect nanoparticles from capture by 
macrophages. The increased hydration also 
helps nanoparticles to be more water soluble 
and less sensitive to enzymatic degradation, 
there fore enhancing biocompatibility. 
  During past decade, the application of 
polymer based drug delivery systems in 
oncology exponentially with advent of 
biodegradable polymers. In these polymers, 
drugs are physically dissolved, entrapped, 
encapsulated or covalently attached to the 
polymer matrix. The resulting compounds may 
have different structures including micelles and 
dendrimers. Both natural (albumin, Chitosan, 
Heparin etc) and Synthetic ( Poly-L- Lactide, 
Poly- [L-glutamate] Poly [D, L Lactide-Co-
glycolide], [PEG, etc], biodegradable polymers 
are being exploited as drug delivery systems. 
Targeted Delivery of Therapetic Nano Particles 
  Nanoparticle delivery of anticancer 
drugs to tumor tissues can be achieved by either 
passive or active targeting. 
  Passive targeting takes advantage of the 
inherent size of nanoparticles of tumour 
vasculature, such as the enhanced permeability 
and retention effect (EPR) and the tumour 
microenvironment. This approach can 
effectively enhance drug bioavailability and 
efficacy. 
  Angiogenesis is crucial to tumour 
progression. Blood vessels in tumour tissues 
have gaps as large as 600 to 800 nm between 
adjacent endothelial cells. This defective vascular 
architecture coupled with poor lymphatic 
drainage includes EPR effect which allows 
nanoparticles to extravasate through these gaps 
into extra vascular spaces and accumulate inside 
tumour tissues. 
  The accumulation of nano particles in 
tumours depend on factors including the size, 
surface characterstics and circulation half-life of 
the nano particles and the degree of 
angiogenesis of the tumour. 
  Hyper proliferative cancer cells have 
profound effects on their surrounding 104 
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microenvironment. Tumours must adapt to use 
glycolysis (hypoxic metabolism) to obtain extra 
energy, resulting in an acidic microenvironment. 
In addition cancer cells over express and release 
some enzymes that are crucial to tumor 
migration, invasion and metastasis, including 
matrix metalloproteinases (MMP). When certain  
PH-sensitive molecules are incorporated into 
liposomes, drugs can be specially relased from 
the complexes by change in PH. The PH-
sensitive liposmes are stable at physiologic 
conditions (PH 7.2) but degraded in tumour-
associated acidic area1. 
  The polymeric nanoparticles that have 
been tested clinically so far have mostly lacked a 
targeting moiety and instead relay mainly on the 
EPR effect of tumours, the tumour 
microenvironment, and tumour angiogenesis to 
promote some tumour selective delivery of 
nanoparticles to tumour tissues. However, these 
drug delivery systems have intrinsic limitations 
to the degree of targeting specificity they can 
achieve. In the case of the EPR effect, while 
poor lymphatic drainage on the one hand helps 
extravasated drugs to be enriched in the tumour 
interstitium on the other hand, it induces drug 
outflow from the cells as a result of higher 
osmotic pressure in the interstitium, which 
eventually leads to drug redistribution in some 
portions of the cancer tissue1. 
To overcome these limitations a 
targeting ligand or an antibody is conjugated to 
nanoparticles. By incorporating a targeting 
molecule that specifically binds an antigen or 
receptor that is either uniquely expressed or over 
expressed on tumour cell surface, the ligand-
targeted approach is expected to selectively 
deliver drugs to tumour tissues with greater 
efficiency. Such targeted nanoparticles may 
constitute the next generation of polymeric 
nanoparticle drug delivery system. Indeed, 
several targeted polymeric nanoparticle are 
currently undergoing preclinical studies. 
Choice of Target Receptor 
  Selection of the appropriate receptor or 
antigen on cancer cells is crucial for the optional 
design of targeted nanoparticles. The ideal 
targets are those that are abundantly and 
uniquely expressed on tumour cells, but have 
negligible or low expression on normal cell. 
Whether the targeted nano-conjugate can be 
internalized after binding to the target cell is 
another important criterion in the selection of 
proper targeting ligands. The concentration of 
drug is much higher when the drug is released 
from nanoparticles in the cytoplasm after 
internalization1 
Choice of targeting ligand 
  One of the greatest challenges to the 
design of nanoparticles than can selectively and 
successfully transport drug to cancerous tissues 
is the choice of targeting agents. 
  A variety of tumour targeting ligands, 
such as antibodies, growth factor, or cytokines, 
have been used to facilitate the uptake of carrier 
into target cells. 
  Ligands targeting cell-surface receptors 
can be natural materials like folate and growth 
factors, which have the advantages of lower 
molecular weight and lower immunogenicity 
than antibodies. However, some ligands, such as 
folate that is supplied by food, show naturally 
high concentration in the human body and may 
compete with the nano-particle-conjugated 
ligand for binding to the receptor reducing 
intracellular concentration of delivered drug. 
Recent advances in molecular biology allow 
modified antibodies to be used as targeting 
moieties in an active-targeting approach. MAbs 
or antibody fragments are most frequently used 
ligands for targeted therapies. Whole MAbs have 
two binding domains showing high binding 
avidity. The Fc domain of MAb can induce 
complement mediated cytotoxicity leading to 
additional, cell- killing effect1 
  The use of antibody fragments as 
targeting moiety can reduce immunogenicity and 
improve pharmacokinetic profiles of 
nanoparticles. 
Future directions 
  Recent advances in molecular, 
biological and genetic diagnostic techniques 
have begun to explore cancer-associated 
biomarkers and their implications for 
development and progression of cancer and to 
reveal that cancer is controlled by complex 
multi-factorial mechanism rather than single 
factor 
  Molecularly targeted therapy is a recent 
introduction with understanding of the cancer 
behaviours at the molecular level.  Assays to 
accurately and quickly quantify several cancer–
related biomarkers simultaneously on single 
tumour specimens will be enabled by virtue of 105 
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advances of nanotechnology for example : use 
of conjugated quantum Dots potentially allows 
five cancer – related proteins to be detected on 
same tissue section. 
  In addition to ex vivo analysis for the 
detection of early cancer and profiling of 
molecular biomarkers, in vivo imaging of cancer 
using several types of nanoparticles has also 
been investigated together with the progression 
of nanoscale drug  delivery system. The 
development of multifunctional nanoparticles 
may contribute significantly to the realization of 
individualized therapy for cancer. Ideally, for 
constructing multifunctional nanoparticles, an 
appropriate combination of agents (Therapeutic 
agent and targeting moiety) will be chosen based 
on accurate biological information with the 
tumour with imaging materials attached on the 
nanoparticle surface. Nanoparticles may 
eventually be capable of detecting malignant 
cells, pinpointing and visualizing their location 
in the body, killing the cancer cells with minimal 
side effects by sparing normal cells and 
monitoring treatment effects in real time. 
           There are certain critical questions that 
need to be addressed in the rational design and 
applications of nanoparticles before further 
clinical development, such go how the 
association or conjugation  of  a therapeutic 
agent to ligand  or carrier changes the 
pharmakinetics, biodistribution and side effects 
of nanotherapecitic drugs, how the safety profile 
of a nanoparticles  changed after  conjugation , 
such an coating with quantum Dots, how we 
can minimize the potentical toxicity of 
polymeric nanoparticles that is inherent from 
the accumulation of a  nonbiodegradable  
polymer with size over renal threshold and how 
side effects resulting from the ability of 
nanoparticles to cross the BBB  can be 
prevented or diminished. These questions are 
critically important and hitherto under studied 
   Attracted by the rapid and promising progress 
in nanotechnology, physicists, chemists, 
engineers, biologists and clinicians will continue 
to challenge themselves to develop novel and 
efficacious nanosystems for the diagnosis and 
treatment of cancer. 
Possible Risk for human health and Ethical 
Questions   
              While products based on 
nanotechnology are actually reaching the market, 
sufficient knowledge on the associated 
toxicological risks in still lacking. The literature 
on toxicological risks of the application of NT 
in medical technology in scarce. 
Reducing the size of structure to nano 
level results in distinctly different properties. As 
well as the chemical composition, which largely 
dictates the intrinsic toxic properties very small 
size appears to be a dominant indicator for 
drastic or toxic effects of particles. It is generally 
accepted that nanoparticles pose a separate 
problem with in the area of toxicology, 
designated an nanotoxicology.4  
   Therefore, chemicals and materials in 
nanoformulation need to be evaluated for their 
activity and toxicity as nanoparticles. Chemical 
composition, which dictates the intrinsic toxic 
properties of the chemical, is significant 
importance in determining the toxicity of 
particles. 
It has been found that biodegradable 
substances are normally decomposed and their 
waste products excreted by the kidneys and 
intestines. However, nonbiodegradable 
nanoparticles have been studied and it seems 
that they accumulate in certain organs, especially 
to the liver. It is not clarified, the potential harm 
they may trigger, or at what dosage, but further 
investigation is need. 
Ethical and moral concerns also need to be 
addressed in parallel with the new developments 
in some areas, for example, neuroethics need to 
be investigated  before brain and neural system 
research.   
Conclusion 
Nanotechnology is fast expanding area of 
research anticipated to lead to development of 
novel, sophisticated applications which 
recognize cancer cells, deliver drugs to target 
tissue, reporting out come of  therapy, monitor 
intracellular changes to help prevent 
precancerous cells from becoming malignant. 
The future remains exciting and wide open for 
ongoing efforts by scientists, researchers and 
medical personnel can sincerely ensure to do big 
things using the very small.  
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